Malignant Laryngeal Neoplasm — Variants & evidence

Malignant Laryngeal Neoplasm — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

2 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items (2 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E1
Vemurafenib	Laryngeal Squamous Cell Carcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID5962 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
PTPN11 Overexpression1
(prognostic)	Laryngeal Carcinoma	Prognostic	B	Supports Poor Outcome	2	accepted	EID1316 Study explored the expression of the PTPN11 protein (SHP2) and found that expression was increased in a cohort of 112 laryngeal cancer samples. Expression was also associated with poor survival (p=.02… (full text at CIViC) PMID 24297342 · Gu et al., 2014 · Open in CIViC	civic

Data updated 21 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.